Dr. Rahul Kushwah reports

QSCREEN AI COMPLETES PLATFORM THAT IDENTIFIES PROBABLE DRUG A PERSON HAS CONSUMED IN REAL TIME FROM A CAMERA ALONE - TARGETS CORRECTIONAL FACILITIES FACING CORONER SCRUTINY OVER WITHDRAWAL DEATHS

QScreen AI Inc. today provided a commercialization update. The company has completed development of its QAI physiological AI (artificial intelligence) clinical platform and has commenced outreach to prospective facility partners across correctional health and national defense verticals in Canada and the United States. The platform is complete, patent protected and available for immediate deployment. The company is actively working toward its first signed evaluation agreement.

The QAI platform is the only system capable of identifying the probable substance a person has consumed -- alcohol, opioid, benzodiazepine, stimulant or cannabis from a standard laptop camera alone, in real time, without a blood test, breathalyzer or urine sample. When the physiological reading is inconsistent with what the individual self reported, the platform automatically flags the discrepancy and generates a documented clinical alert before intake is complete which is the capability that has the potential to prevent a withdrawal death in a cell overnight.

The platform simultaneously administers 13 validated clinical instruments including CIWA-Ar, COWS, C-SSRS, LSI-R and PREA-R, produces NCCHC-compliant documentation, and delivers a complete risk-stratified intake summary in under seven minutes with no hardware installation and no IT project. The company holds a granted United States patent on physiological impairment screening. The QAI platform processed over 720,000 real-world scans across global deployments including Tier 1 live-event deployments and workplace safety installations across multiple jurisdictions.

Canadian correctional health market

In Canada, the company has commenced outreach to provincial correctional health authorities in Alberta and Ontario. Both provinces have experienced in-custody deaths attributed to inadequate withdrawal screening at intake, resulting in coroner jury recommendations issued in 2024 and 2025 that explicitly call for clinical substance assessment tools at the point of admission. These recommendations are addressed to the respective provincial ministries, which are obligated to respond within six months of issuance. Management believes the documented clinical need, active coroner accountability processes and the platform's direct relevance to the stated recommendations create conditions supportive of near-term evaluation discussions.

Dr. Rahul Kushwah, chief operating officer of QScreen AI, stated: "We have spent the past year building something that does not exist anywhere else in this market, a platform that tells a nurse, in real time and from a camera, not just that someone is impaired but what they have consumed. We have the patent, the validated instruments and 720,000 scans of real-world data behind the models. The platform is complete. We are now in active outreach to facilities that have an urgent, documented need for exactly what we have built. The next milestone is a signed evaluation agreement, and that is what we are working toward."

U.S. engagement via Global Frontier Advisors

Building on its previously announced engagement with Global Frontier Advisors LP (GFA), the company is advancing structured discussions across United States correctional health and national defence verticals. GFA is led by Lieutenant General Michael S. Groen (Retired), former director of the United States Department of Defense Joint Artificial Intelligence Center (JAIC). GFA holds equity-based and performance-based compensation aligned with the company's commercial milestones.

The company is advancing outreach and discussions across three primary verticals, with additional verticals to be announced separately:

• U.S. correctional health: Approximately 4,800 federal, state and local correctional facilities process 7.9 million jail admissions annually. Coroner's juries across North America have explicitly recommended clinical substance assessment tools at intake. GFA is advancing discussions with target facilities from an identified addressable pipeline of 300 to 500 facility deployments.
• National Defence and Department of Defense: The U.S. Department of Defense manages approximately 4,800 military sites worldwide. GFA is advancing discussions across personnel readiness screening and work force health programs.
• TSA and federal security: Approximately 50,000 Transportation Security Officers screen passengers at nearly 440 federalized airports nationwide. The platform supports preshift physiological fitness for duty assessment without metabolite testing.

About QScreen AI Inc.

QScreen AI is an emerging provider of rapid health screening and remote patient care solutions globally. The company's Smarthealth AI stations are powered by a proprietary artificial intelligence and use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue and various mental illnesses. QScreen AI's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes.

We seek Safe Harbor.